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Abstract 
Background: The UK Biobank is a unique resource for biomedical research, with 
extensive phenotypic and genetic data on half a million adults from the general 
population. We aimed to examine the effect of neurodevelopmental copy number 
variants (CNVs) on the cognitive performance of participants. 
Methods: We used Affymetrix Power Tools and PennCNV-Affy software to analyse 
Affymetrix microarrays of the first 152,728 genotyped individuals. We annotated a list 
of 93 CNVs and compared their frequencies with control datasets. We analysed the 
performance on seven cognitive tests of carriers of 12 CNVs associated with 
schizophrenia (N = 1,087) and of carriers of another 41 neurodevelopmental CNVs 
(N = 484). 
Results: The frequencies of the 93 CNVs in the Biobank subjects were remarkably 
similar to those among 26,628 controls from other datasets. Carriers of 
schizophrenia-associated CNVs and of the group of 41 other neurodevelopmental 
CNVs had impaired performance on the cognitive tests, with nine of 14 comparisons 
remaining statistically significant after correction for multiple testing. They also had 
lower educational and occupational attainment (p-values between 10-7 and 10-18). 
The deficits in cognitive performance were modest (z score reductions between 0.01 
and 0.51), compared to individuals with schizophrenia in the Biobank (z score 
reductions between 0.35 and 0.90).   
Conclusions: This is the largest study on the cognitive phenotypes of CNVs to date. 
Adult carriers of neurodevelopmental CNVs from the general population have 
Kendall	K	et	al	 3	
significant cognitive deficits. The UK Biobank will allow unprecedented opportunities 
for analysis of further phenotypic consequences of CNVs.   
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Introduction 
Copy number variants (CNVs) are >1,000 base pair DNA segments that are present 
at a variable copy number in comparison with a reference genome (1, 2). CNVs may 
be recurrent and have similar breakpoints when they are formed by non-allelic 
homologous recombination between sites of low copy repeats, or non-recurrent, with 
variable breakpoints, when formed as a result of defects in DNA replication or repair 
(3). There is an increased rate of CNVs in neurodevelopmental spectrum disorders 
including intellectual disability (ID), autism spectrum disorder (ASD) (4, 5), epilepsy 
(6) and schizophrenia (7). To date, 12 CNVs have been robustly associated with risk 
of schizophrenia and they also increase risk of ASD and ID (7, 8). Many more CNVs 
are implicated in ID, ASD and cases with congenital anomalies (4, 5) but have not 
been implicated in schizophrenia, although this could be due to insufficient statistical 
power (8). 
The phenotypes of many highly penetrant CNVs, such as those implicated in Prader-
Willi/Angelman or DiGeorge Syndrome, are well established. Many others have 
incomplete penetrance (9) and their phenotypic spectrum is not fully established 
(e.g. 1q21.2 duplication, 15q11.2 deletion). There are many adult carriers of 
incompletely penetrant CNVs in the general population, who have escaped the 
development of early-onset developmental disorders and are apparently healthy. 
However, they might still have an increased burden of cognitive or physical 
impairments.  
Limited data, based on relatively small sample sizes, are available on the cognitive 
phenotypes of CNVs in adults. An Icelandic study of 144 carriers of 11 pathogenic 
CNVs found that healthy CNV carriers had impaired cognition and performed 
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intermediately between non-CNV carriers and individuals with schizophrenia (10). An 
Estonian study of 56 CNV carriers found an association between rare CNVs and 
lower educational attainment (11).  
The UK Biobank provides a great opportunity to study the effects of pathogenic 
CNVs on physical and mental health characteristics, especially the incompletely 
penetrant ones. The half a million individuals recruited by the Biobank have provided 
extensive demographic, health and cognitive data, will be followed up prospectively 
and are being genotyped on Affymetrix microarrays. We aimed to identify pathogenic 
CNVs in the first 152,728 individuals in the UK Biobank for whom genotype data 
have been released so far and to analyse the cognitive consequences of 
neurodevelopmental CNVs. 
 
Methods and Materials 
Participants: The UK Biobank (www.ukbiobank.ac.uk) recruited half a million 
participants in the UK between 2006 and 2010, aged 40-69 years, 53% female. All 
subjects provided informed consent to participate in UK Biobank projects and agreed 
to have their health followed over many years. Ethical approval for the study was 
granted by the North West multi-centre ethics committee. The Biobank used 22 
assessment centres in England, Scotland and Wales. Participants were recruited 
from National Health Service (NHS) patient registers, with no exclusion criteria, 
provided they lived within a reasonable proximity to an assessment centre. 
Participants spent approximately three hours at the assessment centres, providing 
detailed demographic, socioeconomic and health related data via a touch screen 
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questionnaire. Following this, a trained nurse performed an interview to clarify any 
questions arising from the touch screen questionnaire. Participants underwent 
several physical assessment measures and provided blood, urine and saliva 
samples. Data were released to Cardiff University following application to the UK 
Biobank. 
Genotyping: Samples were genotyped at Affymetrix Research Services Laboratory, 
Santa Clara, CA. Around 100,000 samples were genotyped on the UK Biobank 
Axiom Array (820,967 probes) and ~50,000 samples were genotyped on the UK 
BiLEVE Array (807,411 probes) (12). There is 95% common content between the 
two arrays 
(https://biobank.ctsu.ox.ac.uk/crystal/docs/genotyping_sample_workflow.pdf). 
Sample processing at UK Biobank is described in the Supplementary Material. Here 
we present data from 152,728 individuals genotyped in the first phase of genotyping, 
of which 151,659 passed our quality control (QC) filters (Table S1). 
CNV Calling: In our previous work on CNVs, we analysed datasets of up to 20,000 
samples at a time (13-16). In order to call CNVs in the UK Biobank, we had to 
substantially increase the speed of processing, by analysing batches in parallel, 
standardising QC processes across all batches, and omitting z score analysis of 
CNVs, re-clustering after removal of poorly performing samples, and manual 
inspection of CNV traces. Anonymised genotype data were downloaded as raw 
(CEL) files from the UK Biobank website, stored on a secure Linux server and 
analysed with UNIX-based commands (detailed in the Supplementary Material, 
Section 2). Briefly, we used the apt-probeset-genotype command with Affymetrix 
Power Tools (APT) software 
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(www.affymetrix.com/estore/partners_programs/programs/developer/tools/powertool
s.affx) to generate normalised signal intensity data, genotype calls and confidences. 
We analysed only the ~750,000 biallelic markers as these can be used in PennCNV-
Affy to generate cluster plots. Each pre-defined batch of ~4,600 CEL files was 
analysed separately, to reduce potential batch effects. The genotype calls, 
confidences and summary files were processed with PennCNV-Affy software (17). 
We generated canonical genotype clusters, Log R Ratios (LRR) and B Allele 
Frequencies (BAF) and completed the subsequent steps recommended in PennCNV 
for the generation of CNV calls (17). Following CNV detection, adjacent CNVs were 
joined if separated by <25% of their combined length. Individual samples were 
excluded if they had 30 or more CNVs, had a waviness factor (WF) >0.03 or <-0.03 
or a call rate <96%. Individual CNVs were excluded if they were covered by <10 
probes or had a density coverage of <1 probe per 20,000 bp. A total of 1,069 
samples (0.7%) were excluded during QC (Table S1).  
CNV Annotation: We compiled a list of 93 CNVs proposed to be pathogenic in two 
widely accepted sources (4, 5). The full list with the corresponding critical region 
coordinates is presented in Table S2. The breakpoints of the initially called CNVs 
were inspected to confirm that they met our CNV calling criteria (Table S4). Briefly, 
we required a CNV to cover >50% of the critical interval and to include the key genes 
in the region (if known), or in the case of single gene CNVs (e.g. NRXN1) we 
required deletions to intersect at least one exon and duplications to cover the whole 
gene. For comparison of CNV frequencies with previous results, we used data from 
26,628 control individuals from other large datasets, for which we have access to the 
raw CNV data and used the same CNV calling methods (Table S3) (7, 18, 19). As 
not all 93 of these CNVs are known to affect cognition (or such link has not been 
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statistically confirmed), for our analyses we selected 53 of these CNVs that have 
been statistically associated with neurodevelopmental phenotypes (4), (after 
removing the common duplications at 15q11.2, as they would account for over half of 
the “other neurodevelopmental CNVs”, thus skewing all analyses). The 53 CNVs 
were further subdivided into 12 CNVs associated with schizophrenia (7, 8) and the 
remaining 41, denoted as “other neurodevelopmental CNVs” (Table S2).  
Cognitive Tests: Participants completed a battery of cognitive tests organised by 
the UK Biobank. We chose to analyse tests done by at least 10% of participants and 
restricted the analysis to individuals who self-reported as being of white British or 
Irish descent. Different numbers of participants were asked by the Biobank to 
complete the various tests, ranging from nearly the complete sample (Pairs 
Matching, Reaction Time), to only parts of the sample (the remaining tests). The 
scores were first normalised, if not normally distributed, and then converted to z 
scores (Supplementary material, Section 7). We analysed data on the following 
tests: 
Pairs Matching Test (testing episodic memory, completed at the assessment centres 
at the first visit by 136,292 individuals with available genotypes). Participants were 
shown 6 pairs of cards for 3 seconds, which were then turned over. Participants 
were asked to identify the matching pairs. We used the total number of errors made 
during this task and restricted our analyses to individuals who finished the test. We 
applied a log +1 transformation to these data. 
Reaction Time Test (simple processing speed, completed at the assessment centres 
at the first visit by 138,603 individuals with available genotypes). Participants were 
asked to play 12 rounds of a computerised ‘Snap’ game where they had to click a 
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button as quickly as possible when shown two matching cards. We used the mean 
reaction time from their attempts. The data were log transformed. 
Fluid Intelligence Test (reasoning and problem solving, completed at the assessment 
centres at the first visit by 44,575 individuals with available genotypes, i.e. this test 
was not given to everybody). Participants were presented with 13 verbal and 
numerical reasoning questions and had to answer as many as they could, within two 
minutes. We used the total number of correct answers for our analyses. Data were 
normally distributed and did not require transformation. 
Digit Span (numeric working memory, completed at the assessment centres at the 
first visit by 14,495 individuals with available genotypes). Participants were 
presented with progressively longer numbers (maximum 12) and asked to enter 
them back once the number had disappeared. We used the maximum number of 
digits remembered for our analyses. Data were normally distributed and did not 
require transformation. 
Symbol Digit Substitution Test (complex processing speed, completed at follow-up 
on home computers by 33,057 individuals with available genotypes). This test 
involves matching numbers to a set of symbols. We used the number of correct 
substitutions for our analyses. There were small numbers of outliers, that suggested 
technical issues, so we excluded results of <3 and >36 substitutions. The remaining 
scores were normally distributed and did not require transformation. 
Trail Making Test A and B (visual attention, completed at follow-up on home 
computers by 29,251 individuals with available genotypes). Participants were asked 
to connect scattered circles according to numbers (Trail A) and to alternating 
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numbers and letters (Trail B). We used the time taken to complete these tests for our 
analyses and these data were log transformed prior to the generation of z scores. 
For comparison, we also analysed data obtained from 507 individuals from the 
Biobank, who self-reported a diagnosis of schizophrenia at the interviews at the 
assessment centres, because schizophrenia is associated with impaired cognitive 
performance (10). Only 169 of the 507 have been genotyped so far and just three of 
them carried a CNV from our list of 53 loci.  
We calculated the effect size reductions on cognitive tests of the carriers of the two 
CNV groups, and of individuals with schizophrenia, in linear regression analyses, 
corrected for age and sex (Table 1). We also compared the carriers of 
“schizophrenia CNVs” versus those with “other neurodevelopmental CNVs” using 
linear regression analyses, corrected for age and sex (Table 2).  
Educational attainment and occupational level are highly correlated with cognitive 
performance (20, 21). We analysed these variables using ordinal regression with 
CNV carrier status and sex as factors and age as a covariate.  
 
Results 
151,659 samples passed QC (99.3%). 790,761 CNVs were retained after QC 
(without filtering for frequency or size), an average of 5.2 per person (range 0 to 29, 
Figure S1). The frequencies of individual CNVs were consistent between batches, 
indicating a lack of significant batch effects (Table S12). Overall, the CNVs from the 
UK Biobank sample occurred at rates strikingly similar to those among the control 
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datasets genotyped on different arrays and called by us with the same methods 
(Table S2). Only two CNVs reached nominally significant difference between the two 
datasets, but neither survives correction for multiple testing of 93 loci. 3.8% of people 
in the Biobank carry a CNV from the list of 93 that were annotated. (The list of CNVs 
will be made available for download from the UK Biobank.) Of those CNVs, 54 have 
been shown to be significantly associated with neurodevelopmental disorders (4), 
including all 12 schizophrenia CNVs. In the Biobank, 1.12% of participants carried 
one of these neurodevelopmental CNVs (after excluding the common 15q11.2 
duplication, found in 0.5% of subjects). 
Cognitive Test Results: Carriers of both the “schizophrenia CNVs” and the “other 
neurodevelopmental CNVs” had impaired performance on the seven cognitive tests, 
compared to CNV non-carriers, with 9 of the 14 comparisons reaching statistically 
significant differences that survive a conservative Bonferroni correction for multiple 
testing for 14 tests. Table 1 presents these differences, expressed as un-
standardised B coefficients (z scores), corrected for age and sex in linear regression 
analyses. Most differences were modest in magnitude (z scores between 0.01 and 
0.51 below the non-CNV carriers). Individuals with schizophrenia performed worse 
than either group of CNV carriers (z scores between 0.35 and 0.90 below the non-
CNV carriers) and all differences were highly significant. 
<Table 1> 
We then examined the differences in cognitive performance between carriers of the 
12 schizophrenia CNVs (N = 1,087) and carriers of the remaining 41 
neurodevelopmental CNVs (N = 484), generated again from linear regression 
analysis, corrected for age and sex. Their performance tended to be similar (Figure 1 
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and Table 2). Although two of the tests reached nominal levels of statistical 
significance, these do not survive correction for multiple testing for seven tests and 
were in opposite directions (Table 2).  
<Figure 1 and Table 2>  
Educational and Occupational Attainment: We compared the educational and 
occupational attainment of neurodevelopmental CNV carriers against the non-CNV 
carriers. Both groups of CNVs carriers attained lower educational qualifications, e.g. 
a smaller proportion obtained a university/college degree, or achieved A/AS-levels at 
school (post-compulsory education qualifications taken at 16-18 years of age, Figure 
2). We carried out ordinal regression analysis, with qualifications as the dependent 
variable, CNV status and sex as factors and age as a covariate. This indicated lower 
odds (0.61) for carriers of schizophrenia CNVs to finish in a higher qualifications 
group (95% CI 0.55-0.68, Wald 76.3, p = 2.4×10-18). Similar results were found for 
carriers of the other neurodevelopmental CNVs: lower odds (0.54), (95% CI 0.46-
0.64, Wald 52.5, p = 4.4×10-13). CNV carriers also tended to have occupations that 
require less training or academic skills (Figure 3). Ordinal regression analysis, with 
major job group as the dependent variable, CNV status and sex as factors and age 
as a covariate indicated lower odds (0.64) for carriers of schizophrenia CNVs to have 
a job in an occupational group that requires higher skills and longer training, as 
defined by Office of National Statistics (22) (95% CI 0.56-0.73, Wald 43.7, p = 
3.7×10-11). Similar results were found for the carriers of other neurodevelopmental 
CNVs: lower odds (0.58), (95% CI 0.47-0.71, Wald 28.4, p = 1.0×10-7). 
<Figures 2 and 3> 
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Discussion 
CNVs are a rare but important cause of serious neurodevelopmental disorders such 
as ID, ASD, schizophrenia and a variety of congenital malformations (4, 5, 23). The 
UK Biobank sample, with half a million participants, is a unique resource for 
establishing the effects of CNVs on phenotypic outcomes. The data quality was very 
high as indexed by the low fraction of samples that failed our QC (0.7%). Identical QC 
steps allowed us to call reliably the selected set of pathogenic CNVs, but researchers 
wishing to analyse smaller or common CNVs might have to use different filtering 
criteria.  
Frequencies of pathogenic CNVs: We established the frequencies of a set of 93 
CNVs that have been proposed to be pathogenic (4, 5) in ~150,000 participants in the 
UK Biobank genotyped so far (Table S2). We compared these with a large control 
dataset comprising 26,628 people, where we had access to raw CNV data or had 
ourselves called the CNVs from raw microarray files (Illumina or other versions of 
Affymetrix arrays). In the absence of an opportunity to perform technical replication on 
different arrays, we reasoned that finding similar CNV frequencies was the best 
validation of our CNV calling. These were indeed remarkably similar, with just two 
reaching nominally significant differences that would not survive correction for the 
multiple testing involved (Table S2).  
Carriers of CNVs implicated in neurodevelopmental phenotypes have reduced 
cognitive performance: In order to assess the cognitive performance of CNV 
carriers, we first selected, from the 93 annotated CNVs, a list of 54 CNVs that have 
Kendall	K	et	al	 14	
been statistically associated with neurodevelopmental phenotypes, such as ID and 
ASD (4). This was done in order to exclude CNVs that are not confirmed to be 
associated with cognitive impairment (although they could be pathogenic for other 
medical conditions). We excluded from this list the common 15q11.2 duplication, 
found in 0.5% of the sample, as it would disproportionately affect the results.  
Each CNV is likely to have its own set of phenotypic characteristics and cognitive 
signature. It is premature to analyse each one separately, as the study will be better 
powered for such analysis after all participants are genotyped. In order to provide an 
initial sub-group analysis, we divided the CNVs into a set of 12 that have been 
confirmed as associated with schizophrenia (7, 8), and the 41 “other 
neurodevelopmental” CNVs. This division is unlikely to represent an actual dichotomy, 
as all 12 schizophrenia loci are also neurodevelopmental ones and we recently 
proposed (8) that many of the “other neurodevelopmental” CNVs increase risk for 
schizophrenia but this has escaped statistical confirmation, due to their rarity. Our 
finding of similar cognitive deficit among carriers of the two groups provides another 
argument that this distinction is somewhat arbitrary. 
A study on the Icelandic population found reduced cognitive performance in 144 
healthy carriers of 11 pathogenic CNVs: 1q21.2dup, NRXN1 del, 13q31.3dup, 
15q11.2del, 16p12.1del, 16p11.2del+dup, 16p13.11dup, 17p12del+dup and 
22q11.21dup (10). Most of these (except the 13q31.3 duplication and 17p12del and 
dup) are on our list of 53 neurodevelopmental loci. We analysed the participants’ 
performance on seven cognitive tests. In order to allow comparison with previous 
studies (10), we also show results for 507 individuals recruited in the Biobank, who 
self-reported to have schizophrenia, as they are expected to perform even worse on 
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these tests. Carriers of neurodevelopmental CNVs (of both groups) performed 
intermediately between non-carriers and individuals with schizophrenia, with 
reductions between 0.01 and 0.51 standard deviations (z scores), compared with CNV 
non-carriers. The results reached significance on most tests, even if corrected 
conservatively for multiple testing for 14 tests (Figure 1 and Table 1). The two CNV 
groups were similar to each other, and no p-value would survive correction for multiple 
testing (Table 2). Individuals with schizophrenia performed worse than any other 
group on all tests, at 0.35 to 0.90 standard deviations (z score) reductions from non-
CNV carriers.  
It is well established that cognitive performance predicts achievement at school and 
employment (20, 21, 24). Here we show that adult carriers of neurodevelopmental 
CNVs also had lower educational attainment and tended to have occupations 
requiring less time in training, with all comparisons being highly significant. We 
wanted to address the question whether the effect on school/occupational attainment 
is entirely explained by a reduction in cognitive performance among CNV carriers. We 
tested in a logistic regression analysis the effect of CNV carrier status on educational 
and occupational attainment, with and without the fluid intelligence score as a 
covariate (this test showed the highest effect size). Most of the effect of the CNV 
status on education/occupation was explained via the effect of the fluid intelligence 
score (Table S7), indicating that, whilst cognitive impairment has a major effect on 
educational and occupational attainment, other phenotypic consequences of having a 
pathogenic CNV also play a role (Supplementary Material). We note that 30.9% of 
carriers of neurodevelopmental CNV hold managerial or professional occupations and 
that the distribution of their cognitive tests performance overlaps with that of non-CNV 
carriers, with only a modest shift (Figure S7c as an example for the Fluid Intelligence 
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test scores). This suggests that significantly impaired performance in the presence of 
a pathogenic CNV is not inevitable, at least for many CNV loci. It is possible that these 
highly functioning individuals may have performed even better, had they not carried a 
CNV. It has been suggested (25) that pathogenic CNVs produce a consistent degree 
of cognitive impairment, in the context of the individual’s genetic background (e.g. by 
2 SD in the case of 22q11.2 deletions). Our results for the Fluid Intelligence Test are 
consistent with this observation (Figure S7c), albeit with a more modest difference. 
The majority of previous studies on pathogenic CNVs have recruited individuals from 
health services for ID, ASD, congenital anomalies or schizophrenia. Much less is 
known about the effects of these CNVs in adults from the general population (9, 10). 
Carriers of neurodevelopmental CNVs had reduced cognitive performance, 
educational and occupational attainment, with highly significant differences compared 
to non-CNV carriers. The effect size however is modest, <0.5 standard deviations for 
all tests, with large overlap between the groups (Figure S7c). We suggest that this 
may partly be explained by many severely affected CNV carriers, such as adults with 
intellectual disability, having not taken part in UK Biobank.  This would result in highly 
functioning individuals being overrepresented. This may be in part due to the 
recruitment strategy and in part because some people with complex disabilities may 
have died before the recruitment age of 40-69 years.  For example, there were only 5 
individuals with 22q11.2 deletions, while we would expect about 37 carriers in a 
population of this size (the rate of this deletion among newborns is ~1:4,000), (9). This 
is a severe disorder, with a decreased IQ of ~30 points, multiple congenital 
malformations and reduced life expectancy. Similarly, there were no cases consistent 
with Prader-Willi/Angelman syndromes or Down’s syndrome and there was only a 
single case with deletion at the Smith-Magenis syndrome region. Individuals with 
Kendall	K	et	al	 17	
schizophrenia are also underrepresented, at only 0.12%, despite the disorder’s 
lifetime risk of 0.4-0.5% (26). An even smaller proportion of such individuals took part 
in the follow-up cognitive tests (e.g. only 7% of individuals with schizophrenia 
completed the Trail Making Tests at follow-up, compared to 21% of the remaining 
participants). Therefore, it is reasonable to assume that, although the UK Biobank 
attempted to recruit a sample that reflects the general population, it probably 
underrepresents seriously affected individuals. By analogy, carriers of pathogenic 
CNVs who have taken part in the UK Biobank might be among the higher functioning 
CNV carriers. The UK Biobank is recognised to be a generalisable sample, rather 
than one that is representative of the general population (27). However, it has been 
suggested that for data sources of this magnitude, data generated can still be applied 
to the population as a whole (28). 
In order to further assess the potential of the Biobank to discover phenotypes caused 
by pathogenic CNVs, we checked whether we can detect the clearly defined 
phenotypes of certain common and incompletely penetrant CNVs. We examined 
CNVs at 16p11.2 (44 deletions and 42 duplications) and 17p12 (84 deletions and 45 
duplications). Deletions at 16p11.2 have been associated with obesity, while 
duplications at the same locus have been associated with reduced weight (29). 
Carriers of deletions and duplications at this locus are expected to have reduced 
cognitive performance (30). In contrast, deletions and duplications at 17p12 cause 
peripheral neuropathies: hereditary neuropathy with liability to pressure palsies 
(HNPP) for deletions (31), or Charcot-Marie-Tooth disease type 1A (CMT1A), for 
duplications (32), but do not have an associated cognitive phenotype. These 
phenotypes were detected with very high levels of statistical significance 
(Supplementary material, Section 8). Thus, there were highly increased rates of 
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peripheral neuropathy but normal cognitive performance in 17p12 CNV carriers, while 
16p11.2 carriers had reduced cognitive performance and increased or reduced BMI 
for deletions and duplications respectively.  
The full Biobank dataset will allow detailed analysis on the health consequences of 
many more individual CNV loci and we will provide our list of CNVs to the Biobank, to 
assist researchers. 
Limitations: There are several limitations to this study. Whilst the UK Biobank made 
attempts to make their sample as representative as possible, the low proportion of 
individuals with severe disorders such as schizophrenia means that the sample 
cannot be considered perfectly representative of the general population (discussed 
above). There was also a considerable variation in the number of people who were 
approached to perform each cognitive test, and it is possible that some tests are more 
likely to have been performed by higher-functioning individuals. This results in large 
variability in power between the tests and limits inferences that may be made for the 
tests with a lower completion rate.  
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Legends to Figures 
 
Figure 1. z score differences in cognitive performance. The figure shows the z 
scores differences for seven cognitive tests in the different groups of individuals, after 
correction for age and gender in a linear regression analysis. The bars represent the z 
score means and s.e. of the means. In blue are the scores among individuals with 
schizophrenia (including those that have not been genotyped). In green are the scores 
of carriers of schizophrenia-associated CNVs, in red those of “other 
neurodevelopmental” CNVs. A minus sign on the x-axis indicates a worse score for all 
tests (e.g. a lower score or a longer time to complete a test). 
 
Figure 2. Distribution of the two groups of CNV carriers and non-CNV carriers in 
each educational qualification group. The British qualifications are grouped as 
follows: College/university degree; A/AS levels or equivalent: qualifications taken at 
16-18 years of age, post-compulsory education; O levels/GCSEs or equivalent: 
qualifications taken at 14-16 years of age, at the end of compulsory education; CSEs 
or equivalent: a predecessor to GCSEs including vocational subjects; NVQ or HND or 
HNC or equivalent: vocational qualifications. Black bars: schizophrenia-related CNV 
carriers; grey bars: “other neurodevelopmental” CNV carriers; white bars: CNV non-
carriers. 
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Figure 3. Distribution of the two groups of CNV carriers and non-CNV carriers in 
each major job group as defined by the Office of National Statistics (22). X-axis 
coding: 1 – Managers and Senior Officials; 2 – Professional Occupations; 3 – 
Associate Professionals and Technical Occupations; 4 – Administrative and 
Secretarial Occupations; 5 – Skilled Trades Occupations; 6 – Personal Service 
Occupations; 7 – Sale and Customer Service Occupations; 8 – Process, Plant and 
Machine Operatives; 9 – Elementary Occupations. Black bars: schizophrenia-related 
CNV carriers; grey bars: “other neurodevelopmental” CNV carriers; white bars: CNV 
non-carriers. 
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Cognitive Test Non-CNV 
Carriers 
Carriers of Schizophrenia 
CNVs 
Carriers of Other 
Neurodevelopmental CNVs  
Individuals with 
Schizophrenia 
N N B (s.e.) p N B (s.e.) p N B (s.e.) p 
Pairs Matching – Number 
of Incorrect Matches  
134781 1048 0.09 
(0.03) 
0.003 463 0.17 
(0.05) 
3.2x10-4 436 0.35 
(0.05) 
7.82x10-14 
Reaction Time – Mean 
Time to Correctly Identify 
Matches  
137053 1073 0.21 
(0.03) 
1.52x10-13 477 0.35 
(0.04) 
9.46x10-16 480 0.69 
(0.04) 
1.05x10-57 
Fluid Intelligence – Score  44107 321 -0.48 
(0.05) 
5.29x10-19 147 -0.51 
(0.08) 
3.97x10-10 168 -0.61 
(0.08) 
2.51x10-15 
Digit Span – Number of 
Digits Remembered  
14343 102 -0.42 
(0.09) 
1.8x10-5 50 -0.01 
(0.14) 
0.931 39 -0.78 
(0.16) 
8.7x10-7 
Symbol Digit Substitution 
– Number of Correct 
32770 204 -0.29 
(0.06) 
3.0x10-6 83 -0.22 
(0.09) 
0.024 42 -0.90 
(0.14) 
8.33x10-11 
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Matches  
Trail Making Test A – 
Time to Complete  
28988 185 0.19 
(0.07) 
0.008 78 0.14 
(0.11) 
0.199 36 0.83 
(0.16) 
1.51x10-7 
Trail Making Test B – 
Time to Complete  
28988 185 0.38 
(0.07) 
2.07x10-8 78 0.28 
(0.10) 
0.008 36 0.72 
(0.15) 
3.00 x10-6 
 
Table 1. Results on cognitive tests in the two groups of CNV carriers and individuals with schizophrenia, compared to non-CNV 
carriers. B indicates the differences from non-CNV-carriers, expressed as z scores (s.e. mean) in linear regression analysis, 
corrected for age and sex. Non-CNV carriers, by definition, have z scores of 0.   
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Cognitive Test N Carriers of 
Schizophrenia CNVs 
N Carriers of Other 
Neurodevelopmental 
CNVs 
B (s.e.) p 
Pairs Matching  1048	 463	 -0.02 (0.05) 0.74 
Reaction Time  1073	 477	 -0.13 (0.06) 0.026 
Fluid Intelligence – Score 321	 147	 0.046 (0.09) 0.63 
Digit Span  102	 50	 -0.39 (0.18) 0.031 
Symbol Digit Substitution  204	 83	 -0.08 (0.12) 0.52 
Trail Making Test A  185	 78	 0.06 (0.13) 0.68 
Trail Making Test B  185	 78	 0.11 (0.13) 0.41 
 
Table 2. Comparison of cognitive tests in carriers of 12 schizophrenia-associated CNVs and individuals with other 
neurodevelopmental CNVs. B indicates the differences between the two groups, expressed as z score (s.e. mean) as in Table 1. P-
values are based on linear regression analysis, as above.  
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Sample Processing and Genotyping 
The UK Biobank obtained two 10ml EDTA vacutainers of blood per participant. DNA 
was extracted and purified using a modified Maxwell 16 Blood DNA Purification Kit 
(Promega – AS1010X) (1). Details of the genotyping processes used are available 
on the UK Biobank website. Briefly, samples were genotyped at the Affymetrix 
Research Laboratory, Santa Clara, CA on 96-well plates. Samples were genotyped 
on two very similar arrays with ~95% probe overlap between them: 
1. The UK Biobank Axiom Array includes over 820,000 variants, providing 
comprehensive coverage of the genome and including rare coding variants, 
pharmacogenomics markers, and extra coverage for known copy number 
regions, the HLA region, genes involved in inflammation and eQTL variants. 
2. The UK BiLEVE array was designed for a University of Leicester project 
investigating genetic variation in Chronic Obstructive Pulmonary Disease 
(COPD). Approximately 50,000 participants in the UK Biobank were genotyped 
on this array prior to the introduction of the UK Biobank Axiom Array. The UK 
BiLEVE Array contains 807,411 probes. 
 
CNV Calling at Cardiff University  
Anonymized genotype data were downloaded as raw CEL files in batches of 1,000 
files from the UK Biobank using an authentication key. They were stored and 
processed on a secure UNIX server.  
For the initial step, we used the Affymetrix Power Tools software downloaded 
from the Affymetrix website 
(http://media.affymetrix.com/partners_programs/programs/developer/tools/powertool
s.affx). We used the apt-probeset-genotype command on batches of ~4,600 files 
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using library files for the two arrays downloaded from the Affymetrix website and the 
following parameters: 
/apt-probeset-genotype --analysis-files-path /Axiom_UKB_WCSG.r3/ --xml-file 
/Axiom_UKB_WCSG_96orMore_Step2_Bi-allelic.r3.apt-probeset-
genotype.AxiomGT1.xml --out-dir /Batch1 --summaries --cel-files cel.list_batch1.txt  
This command (example given arbitrarily for Batch1) creates four files that are 
required for subsequent steps: 
AxiomGT1.calls.txt – genotype calls 
AxiomGT1.confidences.txt – confidences for the genotype calls 
AxiomGT1.report.txt – summaries for the samples analyzed including the 
computed gender, call rate and heterozygosity 
AxiomGT1.summary.txt – normalized intensities of A and B alleles 
We used only biallelic markers for our CNV calls as they are utilized by the 
PennCNV software for the creation of genotype clusters. Of the original ~835,000 
markers, this left ~750,000 markers for analysis (Table S1 for details on each batch). 
Other researchers may use different .xml files and different steps, here we only 
present the methods we used. 
For subsequent steps, we used the PennCNV-Affy program to complete CNV 
calling (http://penncnv.openbioinformatics.org/en/latest/user-guide/affy/). This free 
software has been developed and maintained by Dr Kai Wang and colleagues (2). 
First, we generated canonical genotype clustering files from the above files, e.g.: 
/generate_affy_geno_cluster.pl AxiomGT1.calls.txt AxiomGT1.confidences.txt 
AxiomGT1.summary.txt --nopower2 -locfile mapfile.dat -sexfile sex_batch1.txt -out 
batch1.genocluster 
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As the signal intensity values had not been log2 normalized, the –nopower2 
argument was used. We are grateful to Dr Wang for suggesting this solution. 
Next, we calculated Log R Ratio (LRR) and B-Allele Frequency (BAF) values 
using the normalize_affy_geno_cluster.pl command, e.g.: 
normalize_affy_geno_cluster.pl batch1.genocluster AxiomGT1.summary.txt -
nopower2 -locfile mapfileAX.dat -out batch1_lrr_baf.txt 
From here, our analyses followed the Affymetrix CNV Calling Overview 
described on the PennCNV website 
(http://penncnv.openbioinformatics.org/en/latest/user-guide/affy/).  
Briefly, we split the signal files into individual files for CNV calling by 
PennCNV and then detected the raw CNV calls. We created pfb and gcmodel files 
from existing data and “trained” a .hmm file on 100 Axiom samples, using the 
available Affy 6.0 hmm file as a template. 
 
Quality Control (QC) Filtering 
We examined the distribution of the QC parameters, which we routinely used in our 
previous work to filter samples. Individuals were filtered out if they were outliers for 
the following parameters: if they had >30 CNVs (Figure S1), had a genotype call rate 
<96% (Figure S2), had a waviness factor (WF) >0.03 or <-0.03 (Figure S3). We 
decided not to filter on LRR SD (Figure S4). These are quite relaxed filtering criteria, 
compared to those we used in our previous studies (e.g. (3)). We wanted to review 
the results with these filtering steps first, and then filter more stringently if needed. As 
explained in the main text, the pathogenic CNVs were called confidently with these 
criteria, so we saw no reason to filter more stringently. Other researchers might want 
to set different filters, especially if analyzing small or common CNVs. 1,020 samples 
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were excluded using these filters. This number varied between 0 and 146 samples 
for individual batches (see below, Table S1). We re-clustered Batch 14 after 
excluding 114 failed samples to see if this resulted in better quality CNVs in the 
remaining samples. The resulting set of CNVs in the re-clustered samples was 
practically identical, showing that the small number of bad samples did not introduce 
important biases in CNV calling. We elected not to repeat this process for other 
batches.  
 
 
Figure S1. Distribution of the number of CNVs per person, before filtering (all CNVs 
included, starting from those called with 3 probes). We filtered out samples with 30 
or more CNVs. Another 160 samples are not included in the graph, to improve the 
visualisation, as they had >120 CNVs each, ranging up to 1207 CNVs.  
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Figure S2. Distribution of genotype call rate scores before filtering. We excluded 
samples with a SNP call rate of <96%. The full distribution of samples is shown. 
 
 
 
Figure S3. Distribution of the waviness factor (WF), before filtering. We excluded 
samples with WF >0.03 and <-0.03. The full distribution of samples is shown. 
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Figure S4. Distribution of the Log R Ratio standard deviation (LRR SD) scores. The 
full distribution of samples is shown. We decided not to filter on LRR SD, because 
poorly performing samples still picked up the pathogenic CNVs at similar rates.  
 
 
Annotation of CNVs 
For our annotations, we selected 93 CNVs proposed as possible intellectual 
disability CNVs in two of the largest and best-known studies (4, 5). These CNVs and 
their critical regions are shown in Table S2. The original papers divided some of the 
regions into sub-regions. To simplify the presentation and interpretation we grouped 
such regions together (e.g. “large” and “small” 22q11.2 CNVs are presented as the 
same). We used a script to annotate these CNVs in each batch and then manually 
inspected the positions of the annotated CNVs, filtering out those that did not cover 
the correct interval. Whilst it is relatively straightforward to call recurrent CNVs when 
their breakpoints are close to the low copy repeats (LCR) flanking such CNVs, in 
Kendall et al.  Supplement 
8 
some cases this is not so obvious. For example, we had to decide how to call CNVs 
that do not cover the full critical region. We compiled a set of rules to facilitate this 
process (Table S4). As a general rule, a CNV was called if it covered >50% of the 
region, including any key genes in that region (if known). In the case of single gene 
CNVs, deletions were called if they intersected an exon. For duplications of single 
genes, we required the whole gene to be duplicated. If a CNV covered two known, 
adjacent loci, we called it according to the more pathogenic of these loci. If a CNV 
was >20Mb in size, we did not give it the name of a specific CNV locus, but instead 
called it “large” even if it included a known CNV. Some loci had specific rules (Table 
S4). Other researchers may elect to use other criteria in the annotation of CNVs. 
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Samples Processed by Stage and Batch 
Table S1. Samples processed at each stage per batch.  
Batch CEL Genotype Cluster LRR/BAF 
Initial 
CNVs 
QC 
CEL 
Excluded 
samples 
Final 
CNVs 
1 4708 834897 757018 756750 30266 4705 3 23977 
2 4656 834845 759759 759490 31374 4652 4 24476 
3 4648 834837 757910 757636 29291 4648 0 23197 
4 4651 834840 759630 759364 29809 4650 1 23732 
5 4661 834850 758994 758727 30253 4658 3 24035 
6 4688 834877 759928 759660 30978 4686 2 24434 
7 4677 834866 760538 760259 34025 4672 5 26013 
8 4755 834944 760228 759953 30351 4754 1 24055 
9 4692 834881 761596 761319 31252 4689 3 24373 
10 4713 834902 760493 760494 31809 4709 4 24616 
11 4700 834889 759773 759506 28644 4699 1 22658 
12 4705 834894 760790 760510 28374 4701 4 22506 
13 4691 834880 759337 759071 28913 4691 0 22792 
14 4708 834897 757404 757140 25011* 4594 114 20509 
15 4713 834902 757852 757594 27731 4699 14 21094 
16 4604 834793 759225 758962 39377 4491 113 21869 
17 4598 834787 758505 758238 29262 4552 46 23132 
18 4621 834810 757875 757617 36243 4525 96 23188 
19 4626 834815 758296 758036 35166 4490 136 22433 
20 4635 834824 758915 758653 30530 4531 104 22327 
21 4581 834770 759645 759383 27507 4569 12 22048 
22 4719 834908 759932 759663 31807 4709 10 24695 
-1 4540 837704 744454 744161 35746 4498 42 25817 
-2 4551 837715 745106 744816 68699 4465 86 24788 
-3 4530 837695 743842 743559 30807 4527 3 23669 
-4 4548 837712 744820 744536 33428 4548 0 25424 
-5 4531 837695 744490 744199 32012 4528 3 24543 
-6 4526 837690 744022 743728 34067 4437 89 24121 
-7 4532 837696 744520 744244 35741 4515 17 26300 
-8 4557 837721 745555 745270 34516 4554 3 25898 
-9 4537 837701 746022 745729 41317 4391 146 25554 
-10 4563 837727 744593 744303 33977 4560 3 25523 
-11 4563 837727 744880 744584 35378 4562 1 26965 
Batches 1 to 22 were genotyped on the Axiom array, batches -1 to -11 on the BiLEVE 
array. 
CEL – number of CEL files downloaded; Genotype – number of genotypes generated; 
Cluster – number of genotypes following clustering; LRR/BAF – number of Log R Ratios and 
B Allele Frequencies generated; Initial CNVs – initial number of CNVs detected; QC CEL – 
number of samples after QC filtering; Excluded samples – number of individuals excluded; 
Final CNVs – number of CNVs following completion of all QC stages.  
*Batch 14 was re-clustered after removing the 114 failed samples. We show the number of 
CNVs following re-clustering. 
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CNV Breakpoints and Frequencies in the UK Biobank and in the Other 
Control Samples  
 
 
Table S2. CNV loci, their genomic coordinates (according to Feb. 2009 UCSC 
GRCh37/hg19 Assembly) and their frequencies in the UK Biobank and in the other 
control datasets. This list was compiled from studies establishing association of 
these CNVs with neurodevelopmental disorders including developmental delay and 
autism spectrum disorder (4, 5). The “other control” datasets are described 
elsewhere (6-9) and are summarized in the next section. We also show the results of 
a comparison of the frequencies between the two datasets, using Fisher Exact test. 
The CNVs included in our list of “schizophrenia CNVs” and “other 
neurodevelopmental CNVs” are indicated. The last column lists genes from the PSD 
complex that are within the CNV loci (following on our previous work, (10)).  
 
See Supplement 2 (Excel file) for Table S2. 
Kendall et al.  Supplement 
11 
Other Control Datasets 
We established the frequencies of these CNVs in other control datasets, using the 
same criteria as for the UK Biobank. We used a total of 26,628 controls from various 
datasets where we had access to the raw data (or had completed all the analysis 
ourselves), so were able to apply the same criteria. Here we provide a brief list of 
these datasets. Some of these are not strict ‘controls’ but have phenotypes that we 
considered unlikely to be related to our list of pathogenic CNVs, e.g. smoking, 
melanoma. 
 
Table S3. Other control datasets used for comparison of frequencies.  
Dataset Reference Array N after 
QC 
International 
Schizophrenia 
Consortium 
(11)  Affy 5.0, Affy 6.0 3,181 
Molecular Genetics of 
Schizophrenia 
(7) Affy 6.0 3,437 
The Genetic 
Architecture of 
Smoking and 
Smoking Cessation  
dbGaP 
(phs000404.v1.p1) 
(8) 
Illumina 
HumanOmni2.5 
520,766 overlapping 
probes used 
1,488 
High Density SNP 
Association Analysis 
of Melanoma: Case-
Control and 
Outcomes 
Investigation 
dbGaP 
(phs000187.v1.p1) 
(8) 
Illumina 
HumanOmni1_Quad_
v1-0-B 
520,766 overlapping 
probes used 
2,971 
Genetic Epidemiology 
of Refractive Error in 
the KORA Study 
dbGaP 
(phs000303.v1.p1) 
(8) 
Illumina 
HumanOmni2.5 
520,766 overlapping 
probes used 
1,857 
National Blood 
Donors (NBS) Cohort 
(WTCCC2) 
EGA 
(EGAD00000000024) 
(8) 
Illumina 1.2M 
520,766 overlapping 
probes used 
2,375 
1958 British Birth 
Cohort (WTCCC2) 
EGA 
(EGAD00000000022) 
(8) 
Illumina 1.2M 
520,766 overlapping 
probes used 
2,564 
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Dataset Reference Array N after 
QC 
Chronic Obstructive 
Pulmonary Disease 
dbGAP 
(phs000179.v3.p2) 
(9) 
HumanOmni1-
Quad_v1-0-Multi_H 
666,868 overlapping 
probes used 
992 
Corneal dystrophy dbGAP 
(phs000421.v1.p1) 
(9) 
HumanOmni2.5-
4v1_H 
666,868 overlapping 
probes used 
3,529 
Mammography dbGAP 
(phs000395.v1.p1) 
(9) 
HumanOmni1_Quad_
v1-0_B 
666,868 overlapping 
probes used 
954 
Melanoma 2 dbGAP 
(phs000519.v1.p1) 
(9) 
HumanOmniExpressE
xome-8v1_A 666,868 
overlapping probes 
used 
2,416 
Cardiff Controls 
(blood donors) 
Cardiff 
(9) 
HumanOmniExpress-
12v1-1_H  
666,868 overlapping 
probes used 
860 
 
 
We would like to acknowledge the use of these freely available datasets:  
 
International Schizophrenia Consortium (ISC) 
Details of the ISC dataset have been previously published (6). The sample consists 
of six European populations genotyped at the Broad Institute, Cambridge, 
Massachusetts using Affymetrix 6.0 or 5.0 genotyping arrays. We analyzed CNVs in 
3,185 controls. 
 
Molecular Genetics of Schizophrenia (MGS) 
Details of the MGS dataset have been described elsewhere (7). The sample consists 
of individuals of European American ancestry and African American ancestry 
genotyped at the Broad Institute, Cambridge, Massachusetts using Affymetrix 6.0 
genotyping arrays. We analyzed CNVs in 2,556 controls of European American 
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ancestry and 881 controls of African American ancestry (passing QC). CNVs were 
called using the Birdsuite algorithm (12). All individuals with schizophrenia met DSM-
IV criteria for schizophrenia or schizoaffective disorder (13).  
We obtained access to the MGS dataset through dbGaP. Funding support for 
the Genome-Wide Association of Schizophrenia Study was provided by the National 
Institute of Mental Health (R01 MH67257, R01 MH59588, R01 MH59571, R01 
MH59565, R01 MH59587, R01 MH60870, R01 MH59566, R01 MH59586, R01 
MH61675, R01 MH60879, R01 MH81800, U01 MH46276, U01 MH46289 U01 
MH46318, U01 MH79469, and U01 MH79470) and the genotyping of samples was 
provided through the Genetic Association Information Network (GAIN). The datasets 
used for the analyses described in this manuscript were obtained from the database 
of Genotypes and Phenotypes (dbGaP) found at http://www.ncbi.nlm.nih.gov/gap 
through dbGaP accession number phs000021.v3.p2. Samples and associated 
phenotype data for the Genome-Wide Association of Schizophrenia Study were 
provided by the Molecular Genetics of Schizophrenia Collaboration (PI: Pablo V. 
Gejman, Evanston Northwestern Healthcare (ENH) and Northwestern University, 
Evanston, IL, USA).  Funding support for the companion studies, Genome-Wide 
Association Study of Schizophrenia (GAIN) and Molecular Genetics of Schizophrenia 
- nonGAIN Sample (MGS_nonGAIN), was provided by Genomics Research Branch 
at NIMH and the genotyping and analysis of samples was provided through the 
Genetic Association Information Network (GAIN) and under the MGS U01s: 
MH79469 and MH79470. Assistance with data cleaning was provided by the 
National Center for Biotechnology Information. The MGS dataset(s) used for the 
analyses described in this manuscript were obtained from the database of Genotype 
and Phenotype (dbGaP) found at http://www.ncbi.nlm.nih.gov/gap through dbGaP 
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accession numbers phs000021.v2.p1 (GAIN) and phs000167.v1.p1 (nonGAIN). 
Samples and associated phenotype data for the MGS GWAS study were collected 
under the following grants: NIMH Schizophrenia Genetics Initiative U01s: MH46276 
(CR Cloninger), MH46289 (C Kaufmann), and MH46318 (MT Tsuang); and MGS 
Part 1 (MGS1) and Part 2 (MGS2) R01s: MH67257 (NG Buccola), MH59588 (BJ 
Mowry), MH59571 (PV Gejman), MH59565 (Robert Freedman), MH59587 (F Amin), 
MH60870 (WF Byerley), MH59566 (DW Black), MH59586 (JM Silverman), MH61675 
(DF Levinson), and MH60879 (CR Cloninger). Further details of collection sites, 
individuals, and institutions may be found in data supplement Table 1 of Sanders et 
al (15) and at the study dbGaP pages.   
 
The Genetic Architecture of Smoking and Smoking Cessation 
These data were accessed through dbGAP: study accession phs000404.v1.p1. 
Funding support for genotyping, which was performed at the Center for Inherited 
Disease Research (CIDR), was provided by 1 X01 HG005274-01. CIDR is fully 
funded through a federal contract from the National Institutes of Health to The Johns 
Hopkins University, contract number HHSN268200782096C. Assistance with 
genotype cleaning, as well as with general study coordination, was provided by the 
Gene Environment Association Studies (GENEVA) Coordinating Center (U01 
HG004446). Funding support for collection of datasets and samples was provided by 
the Collaborative Genetic Study of Nicotine Dependence (COGEND; P01 CA089392) 
and the University of Wisconsin Transdisciplinary Tobacco Use Research Center 
(P50 DA019706, P50 CA084724). 
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High Density SNP Association Analysis of Melanoma: Case-Control and 
Outcomes Investigation 
These data were accessed through dbGaP: study accession phs000187.v1.p1: 
Research support to collect data and develop an application to support this project 
was provided by 3P50CA093459, 5P50CA097007, 5R01ES011740, and 
5R01CA133996. 
 
Genetic Epidemiology of Refractive Error in the KORA Study 
These data were accessed through dbGaP: study accession phs000303.v1.p1. 
Principal Investigators: Dwight Stambolian, University of Pennsylvania, Philadelphia, 
PA, USA; H. Erich Wichmann, Institut für Humangenetik, Helmholtz-Zentrum 
München, Germany, National Eye Institute, National Institutes of Health, Bethesda, 
MD, USA. Funded by R01 EY020483, National Institutes of Health, Bethesda, MD, 
USA. 
 
National Blood Donors (NBS) Cohort and 1958 British Birth Cohort (Wellcome 
Trust Case Control Consortium 2 - WTCCC2) 
Samples were downloaded from https://www.ebi.ac.uk/ega/ and included samples 
from the National Blood Donors Cohort, EGAD00000000024 and samples from the 
1958 British Birth Cohort, EGAD00000000022. Funding for these projects was 
provided by the Wellcome Trust Case Control Consortium 2 project (085475/B/08/Z 
and 085475/Z/08/Z), the Wellcome Trust (072894/Z/03/Z, 090532/Z/09/Z 
and 075491/Z/04/B) and NIMH grants (MH 41953 and MH083094). 
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Chronic Obstructive Pulmonary Disease (COPD) 
These data from the Genetic Epidemiology of COPD study were accessed through 
dbGaP – study accession phs000179.v3.p2. SNP genotyping data was obtained 
from 998 individuals recruited for a genome-wide association study of chronic 
obstructive pulmonary disease (COPD). These participants had COPD or were 
control individuals who smoked, and were recruited in the USA. They were aged 45-
80 years, white or African American and approximately 50% were male. The 
principal investigators were James D Crapo (National Jewish Health, Denver, CO, 
USA) and Edwin K Silverman (Brigham and Women's Hospital, Boston, MA, USA). 
The study was run at the National Heart, Lung and Blood Institute, Bethesda, MD, 
USA and funded by the National Institutes of Health, Bethesda, MD USA 
(U01HL089897, U01HL089856). 
 
Corneal Dystrophy 
These data were accessed through dbGaP – study accession dbGAP 
phs000421.v1.p1. SNP genotyping data was obtained from 3,640 individuals 
recruited for a genome-wide association study of Fuch’s Endothelial Corneal 
Dystrophy (FECD). Participants had FECD or were control individuals, and were 
recruited in the USA. Participants were 60 years of age or older and approximately 
33% were male. This sample comes from the Genome-Wide Association Study of 
Fuch’s Endothelial Corneal Dystrophy (FECD) held in dbGAP. The principal 
investigators were Natalie Afshari (Duke University, Durham, NC, USA), John 
Gottsch (Johns Hopkins University, Baltimore, MD, USA), Sudha K Iyengar (Case 
Western Reserve University, Cleveland, OH, USA), Nicholas Katsanis (Johns 
Hopkins University, Baltimore, MD, USA), Gordon Klintworth (Duke University, 
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Durham, NC, USA) and Jonathan Lass (Case Western Reserve University, 
Cleveland, OH, USA). Co-investigators were Simon Gregory (Duke University, 
Durham, NC, USA) and Yi-Ju Li (Duke University, Durham, NC, USA). The study 
was funded by the National Eye Institute, National Institutes of Health, Bethesda, 
MD, USA (R01EY016482, CWRU, PI: Sudha Iyengar; R01EY016514, DUEC, PI: 
Gordon Klintworth; R01EY016835, JHU, PI: John Gottsch). Genotyping was carried 
out at the Center for Inherited Disease Research (CIDR), Johns Hopkins University, 
Baltimore, MD, USA and was funded by the National Institutes of Health, Bethesda, 
MD, USA. HHSN268200782096C, NIH contract "High throughput genotyping for 
studying the genetic contributions to human disease"; HHSN268201100011I, NIH 
contract "High throughput genotyping for studying the genetic contributions to human 
disease".  
 
Mammography  
These data were accessed through dbGaP – study accession dbGAP 
phs000395.v1.p1. SNP genotyping data was obtained from 974 women undergoing 
mammography through participation in the San Francisco Mammography Registry 
as part of the Breast Cancer Screening Consortium. This sample comes from the 
California Pacific Medical Center Research Breast Health Cohort held in dbGAP. 
The principal investigator was Elad Ziv (University of California, San Francisco, CA, 
USA). Co-investigators were Steven Cummings (California Pacific Medical Center 
Research Institute and University of California, San Francisco, CA, USA), Karla 
Kerlikowske (University of California, San Francisco, CA, USA) and John Shepherd 
(University of California, San Francisco, CA, USA). The study was run at the 
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA and was 
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funded by the National Institutes of Health, Bethesda, MD, USA (P01 CA107584; 
R01 CA120120). Genotyping was carried out at Johns Hopkins University Center for 
Inherited Disease Research (CIDR), Baltimore, MD, USA and was funded by the 
National Institutes of Health, Bethesda, MD, USA (HHSN268200782096C, "NIH 
contract High throughput genotyping for studying the genetic contributions to human 
disease"; HHSN268201100011I, "NIH contract High throughput genotyping for 
studying the genetic contributions to human disease"). Genotyping quality control 
was carried out at the Genetics Coordinating Center, Dept. of Biostatistics, University 
of Washington, WA, USA. 
 
Melanoma 2  
These data were accessed through dbGaP – study accession dbGAP 
phs000519.v1.p1. SNP genotyping data was obtained from 2,598 individuals 
recruited for a genome-wide association study of melanoma. Participants had a 
diagnosis of cutaneous melanoma or were population-based controls. 52% were 
male. This sample comes from the Study of Melanoma Risk in Australia and the 
United Kingdom study held in dbGAP. The principal investigator was Nicholas 
Hayward (Queensland Institute of Medical Research, Brisbane, QLD, Australia). The 
study was funded by the National Cancer Institute of the National Institutes of Health, 
Bethesda, MD, USA (R01CA088363). Genotyping was carried out at the Center for 
Inherited Disease Research (CIDR), Johns Hopkins University, Baltimore, MD, USA 
and funded by the National Institutes of Health, Bethesda, MD, USA 
(HHSN268201100011I). We refer to this study as Melanoma 2, to point out that it is 
different from the Melanoma study we used in our previous work (8). 
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Cardiff Controls (Blood Donors) 
878 blood donors in the UK were recruited by Cardiff University and blood donation 
centers. These individuals were not screened for psychiatric disorders. However, in 
the UK, individuals cannot donate blood if they are taking medications. Therefore, 
individuals in this dataset are likely to be healthy. 57% of individuals were male. 
 
CNV Calling Criteria 
 
Table S4. Criteria used for calling CNVs. CNVs at EHMT1 and SHANK3 were 
required to intersect at least 1Mbp distance, as small deletions and duplications were 
found to be common in samples with poor QC criteria, indicating that small CNVs in 
these telomeric regions were likely to be false-positives.  
CNV Criteria 
1p36 del/dup Size >50% of critical region, affecting GABRD 
TAR del/dup Size >50% of critical region 
1q21.1 del/dup Size >50% of critical region 
NRXN1 del Exonic deletions 
2q11.2 del/dup Size >50% of critical region, affecting both LMAN2L 
and ARID5A  
2q13 del/dup Size >50% of critical region 
2q13 del/dup (NPHP1) Size >50% of critical region, affecting NPHP1 
2q21.1 del/dup Size >50% of critical region 
2q37 del/dup (HDAC4) Size >50% of critical region, affecting HDAC4 
3q29 del/dup Size >50% of critical region 
Wolf-Hirschhorn del/dup Size >50% of critical region 
Sotos Syn/5q35 dup Size >50% of critical region 
6q16 del/dup (SIM1) Exonic deletions; whole gene duplications 
Williams Beuren Syn del/dup Size >50% of critical region 
7q11.23 distal del/distal dup Size >50% of critical region 
8p23.1 del/dup At least 1Mbp of critical region 
9q34 del/dup (EHMT1) At least 1Mbp CNVs, including EHMT1 
10q11.21q11.23 del/dup Size >50% of critical region 
10q23 del/dup At least 1Mbp, including NRG3 and GRID1  
Potocki-Shaffer Syn del/11p11.2 
dup (EXT2) 
Size >50% of critical region, including EXT2 
13q12 del/dup (CRYL1) Exonic deletions; whole gene duplications  
13q12.12 del/dup Size >50% of critical region 
15q11.2 del/dup Size >50% of critical region 
PWS del/dup Full critical region, ~4Mbp 
Kendall et al.  Supplement 
20 
CNV Criteria 
15q11q13 del/dup BP3-BP4  Size >50% of critical region 
15q11q13 del/dup BP3-BP5 Size >50% of critical region 
15q13.3 del/dup Size >50% of critical region 
15q13.3 del/dup (CHRNA7) Size >50% of critical region, affecting CHRNA7  
15q24 del/dup At least 1Mbp between the A-E intervals 
15q25 del/dup At least 1Mbp between the A-D intervals 
Rubinstein-Taybi del/dup (CREBBP) Exonic deletions; whole gene duplications 
16p13.11 del/dup Size >50% of critical region 
16p12.1 del/dup Size >50% of critical region 
16p12.2-p11.2 del/dup (7.1-8.7 Mb) Size >50% of critical region 
16p11.2 distal del/distal dup Size >50% of critical region 
16p11.2 del/dup Size >50% of critical region 
17p13.3 del/dup (YWHAE) Exonic deletions; whole gene duplications 
17p13.3 del/dup (PAFAH1B1) Exonic deletions; whole gene duplications 
17p12 del (HNPP)/dup (CMT1A) Size >50% of critical region, affecting PMP22 
Smith-Magenis/Potocki-Lupski Syn Size >50% of critical region 
17q11.2 del/dup (NF1) Size >50% of critical region, affecting NF1 
17q12 del/dup Size >50% of critical region 
17q21.31 del/dup Size >50% of critical region 
17q23.1q23.2 del/dup Size >50% of critical region 
22q11.2 del/dup Size >50% of critical region 
22q11.2 distal del/dup Size >50% of critical region 
SHANK3 del/dup At least 1Mbp CNVs, including SHANK3 
“Large” CNVs Size > 20Mbp + >50 genes 
 
 
Kendall et al.  Supplement 
21 
Analysis of Cognitive Tests 
Analyses were carried out on data from cognitive tests performed by UK Biobank 
participants at their first assessment at the assessment centers, or at follow-up on 
home computers. Details of these tests are available on the UK Biobank website 
(http://biobank.ctsu.ox.ac.uk/crystal/). All participants included in these analyses 
were of white British and Irish ancestry.  
 
Pairs Matching Test 
The Pairs Matching Test examines episodic memory. In this test, participants were 
shown cards displaying symbols for 3 seconds (6 cards in the training round and 12 
cards in round 2, the testing round). The cards were then turned over and the 
participant’s task was to identify all correct pairs in as few tries as possible. Data 
collected included the number of correct and incorrect matches per round and the 
time taken to complete the round. We used the number of incorrect matches in round 
2 (field 399) of the Pairs Matching Test (field 100030) as our outcome. We examined 
only results from individuals who achieved 6 correct matches in order to exclude 
results on people who did not complete the test. These results were not normally 
distributed (Figure S5A). We applied a log+1 transformation (Figure S5B) before 
converting them to z scores (Figure S5C). 
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Figure S5A. Distribution of results for the number of incorrect matches in the Pairs 
Matching Test. 
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Figure S5B. Distribution of results for the number of incorrect matches in the Pairs 
Matching Test after log+1 transformation. The resulting values for skewness = -0.334 
and kurtosis = 0.143 are considered acceptable in order to prove normal univariate 
distribution (15). 
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Figure S5C. Distribution of the log+1 transformed results for the number of incorrect 
matches in the Pairs Matching Test after conversion to z scores. 
 
We compared the results (z scores) between both carriers of schizophrenia CNVs (n 
= 1,048) and other neurodevelopmental CNVs (n = 463) with non-CNV carriers 
(134,781) in linear regression analyses corrected for age and sex (Table 1 main 
text). We also compared the results between individuals with schizophrenia and 
those without the disorder in a linear regression analysis, corrected for age and sex 
(Table 1 main text).  
 
Reaction Time Test 
The Reaction Time Test examines simple processing speed. In this test, participants 
were required to play 12 rounds of the card game ‘Snap’. Participants were shown 
Pairs Matching Test - Number of Incorrect Matches (Z Scores)
6420- 2- 4
N
u
m
b
e
r 
o
f 
In
d
iv
id
u
a
ls
25000
20000
15000
10000
5000
0
 
Mean = 
Std. Dev. = 
N = 
Kendall et al.  Supplement 
25 
two cards at a time and were required to press a button as quickly as possible if the 
cards were the same. Data collected included the cards used, the number of times 
the button was pressed, the duration to the first press of the button in each round 
and the mean time to correctly identify matches. We used the mean time to correctly 
identify matches as our outcome (field 20023). These results were not normally 
distributed (Figure S6A). We excluded outlying scores (<100ms and >1500ms) and 
applied a log transformation to the results (Figure S6B) before converting them to z 
scores (Figure S6C).  
 
 
Figure S6A. Distribution of results for the mean time to correctly identify matches in 
the Reaction Time Test in milliseconds. All results are shown. 
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Figure S6B. Distribution for the mean time to correctly identify matches in the 
Reaction Time Test after log transformation. Skewness = 0.692 and kurtosis = 0.985.  
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Figure S6C. Distribution of the log transformed results for the mean time to correctly 
identify matches in the Reaction Time Test after conversion to z scores.  
 
We compared the results (z scores) between both carriers of schizophrenia CNVs (n 
= 1,073) and other neurodevelopmental CNVs (n = 477) with non-CNV carriers (n = 
137,053) in linear regression analyses corrected for age and sex (Table 1 main text). 
We also compared the results between individuals with schizophrenia and those 
without the disorder in a linear regression analysis, corrected for age and sex (Table 
1 main text).  
 
Fluid Intelligence Test 
The Fluid Intelligence Test examines reasoning and problem solving ability of 
participants. In this test, participants were asked to complete as many questions as 
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possible within 2 minutes (maximum score = 13). Data collected included 
participants’ results for each question, the number of questions attempted within the 
time limit and participants’ total scores. We used the number of correct answers 
(field 20016) as our outcome. These results were normally distributed (Figure S7A). 
We converted them to z scores (Figure S7B).  
 
 
 
Figure S7A. Distribution of scores in the Fluid Intelligence Test. Skewness = 0.169 
and kurtosis = -0.147. 
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Figure S7B. Distribution of scores in the Fluid Intelligence Test after conversion to z 
scores.  
 
We compared the results (z scores) between both carriers of schizophrenia CNVs (n 
= 321) and other neurodevelopmental CNVs (n = 147) with non-CNV carriers (n = 
44,107) in linear regression analyses corrected for age and sex (Table 1 main text). 
We also compared the results between individuals with schizophrenia and those 
without the disorder in a linear regression analysis, corrected for age and sex (Table 
1 main text).  
Figure S7c shows the distribution of the raw scores on the 13 questions, 
separately for carriers of schizophrenia CNVs, other neurodevelopmental CNVs and 
non-CNV carriers. The distributions are similar, with a shift towards lower scores 
amongst carriers of schizophrenia and other neurodevelopmental CNVs. 
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Figure S7C. Distribution of scores in the Fluid Intelligence Test in carriers of 
schizophrenia CNVs (green), carriers of other neurodevelopmental CNVs (red) and 
non-CNV carriers (blue).  
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The Digit Span Test examines working memory. In this test, participants were shown 
a two-digit number, which then disappeared from the screen. Participants were 
asked to enter the number they had seen. The number became one digit longer in 
each round (maximum 12). Data collected included target numbers to be memorized, 
the number of correct entries, time to complete the test and the maximum number of 
digits remembered correctly. We used the maximum number of digits remembered 
correctly (field 4282) as our outcome. These results were normally distributed 
(Figure S8A). We converted the results to z scores (Figure S8B).  
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Figure S8A. Distribution of results for the maximum number of digits remembered 
correctly in the Digit Span Test (Numeric Memory Test). Skewness = -0.355 and 
kurtosis = 0.896.  
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Figure S8B. Distribution of results for the maximum number of digits remembered 
correctly in the Digit Span Test (Numeric Memory Test) after conversion to z scores. 
 
 
We compared the results (z scores) between both carriers of schizophrenia CNVs (n 
= 102) and other neurodevelopmental CNVs (n = 50) with non-CNV carriers (n = 
14,343) in linear regression analyses corrected for age and sex (Table 1 main text). 
We also compared the results between individuals with schizophrenia and those 
without the disorder in a linear regression analysis, corrected for age and sex (Table 
1 main text).  
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replace symbols using a number pad within 2 minutes. Data collected included the 
number of matches attempted and the number of correct matches. We used the 
number of symbol digit matches made correctly (field 20159) as our outcome. These 
results were not normally distributed (Figure S9A). We excluded outlying scores (0-1 
and >36) and converted the remaining scores to z scores (Figure S9B).  
 
 
Figure S9A. Distribution of results for the number of correct matches in the Symbol 
Digit Substitution Test. 
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Figure S9B. Distribution of results for the number of correct matches in the Symbol 
Digit Substitution Test after conversion to z scores. Skewness = -0.359 and kurtosis 
= 0.338.  
 
We compared the results (z scores) between both carriers of schizophrenia CNVs (n 
= 204) and other neurodevelopmental CNVs (n = 83) with non-CNV carriers (n = 
32,770) in linear regression analyses corrected for age and sex (Table 1 main text). 
We also compared the results between individuals with schizophrenia and those 
without the disorder in a linear regression analysis, corrected for age and sex (Table 
1 main text).  
 
Trail Making Test 
The Trail Making Test examines visual attention and consists of two parts – numeric 
(A) and alphanumeric (B). In Trail Making Test A, participants must link circles with 
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digits in the correct numeric order. In Trail Making Test B, participants must link 
circles by alternating between numbers and letters of the alphabet. Data collected 
included the total errors made per test, intervals between points and the total time 
taken to complete each test. We used the duration to complete the test as our 
outcome on both tests (TMT A – field 20156, TMT B – field 20157). These results 
were not normally distributed (Figures S10A and S11A). We applied a log 
transformation to the results (Figures S10B and S11B) before converting them to z 
scores (Figures S10C and S11C). 
 
 
 
Figure S10A. Distribution of results for the duration to complete Trail Making Test A. 
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Figure S10B. Distribution of results for the duration to complete Trail Making Test A 
after log transformation. Skewness = 0.665 and kurtosis = 0.624). 
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Figure S10C. Distribution of results for the duration to complete Trail Making Test A 
after conversion to z scores.  
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Figure S11A. Distribution of results for the duration to complete Trail Making Test B. 
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Figure S11B. Distribution of results for the duration to complete Trail Making Test B 
after log transformation. Skewness = 0.482 and kurtosis = 0.449. 
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Figure S11C. Distribution of results for the duration to complete Trail Making Test B 
after conversion to z scores.  
 
We compared the results (z scores) between both carriers of schizophrenia CNVs (n 
= 185) and other neurodevelopmental CNVs (n = 78) with non-CNV carriers (n = 
28,988) in linear regression analyses corrected for age and sex (Table 1 main text). 
We also compared the results between individuals with schizophrenia and those 
without the disorder in a linear regression analysis, corrected for age and sex (Table 
1 main text).  
 
Educational Attainment 
During the collection of socio-demographic information, participants were asked 
“which of the following qualifications do you have?” and options were presented in a 
list (Table S5). Due to the inexact relationship of “other professional qualifications” to 
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the other groups, we excluded individuals who only reported such “other 
qualifications” (n = 7,210). We excluded those who had chosen not to answer this 
question (n = 1,213) and recoded -7 “none of the above” to a new group 6, assuming 
they didn’t obtain a qualification. In this way we created an approximate gradient of 
qualifications. 
 
Table S5. Coding of qualifications and our recoding of this variable.  
Original UK Biobank Groupings Recoded 
1 College/University degree 1 College/University degree 
2 A/AS levels or equivalent 2 A/AS levels or equivalent 
3 O levels/GCSEs or equivalent 3 O levels/GCSEs or equivalent 
4 CSEs or equivalent 4 CSEs or equivalent 
5 NVQ or HND or HNC or equivalent 5 NVQ or HND or HNC or equivalent 
6 Other professional qualifications 
e.g. nursing or teaching 
x Excluded 
-3 Prefer not to answer x Excluded 
-7 None of the above 6 None of the above 
A/AS levels are qualifications taken at 16-18 years of age, post-compulsory education. O 
levels/GCSEs are qualifications taken at 14-16 years of age at the end of compulsory 
education. CSEs were a predecessor to GCSEs, which included vocational subjects. 
NVQs/HNDs/HNCs are vocational qualifications. 
 
 
Occupational Attainment 
Participants were asked their job title and work history. Job codes were allocated 
according to the Office of National Statistics (ONS) Standard Occupational 
Classification (16). We used the major job categories from this classification for our 
analysis (Table S6).  
 
Table S6. ONS major job categories (16). 
Group Number Major Job Group 
1 Managers and Senior Officials 
2 Professional Occupations 
3 Associate Professional and Technical Occupations 
4 Administrative and Secretarial Occupations 
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5 Skilled Trades Occupations 
6 Personal Service Occupations 
7 Sales and Customer Service Occupations 
8 Process, Plant and Machine Operatives 
9 Elementary Occupations 
 
 
In putting together the Standard Occupational Classification, the ONS grouped jobs 
according to skill level. The length of time necessary to become competent at a job 
was used as an approximation of skill level. Within the broad structure of the 
classification, the ONS made reference to four skill levels: 
1. Competence associated with general education, usually acquired by the time 
a person completes their compulsory education. 
2. Knowledge provided via a good general education (as for 1) but with a longer 
period of work-related training. 
3. Knowledge associated with a period of post-compulsory education but not to 
degree level. 
4. Degree or equivalent work experience (16). 
We wondered whether the reductions in educational/occupational attainment 
associated with carrying a CNV (schizophrenia or other neurodevelopmental) might 
be explained by reduced cognitive performance. To answer this question, we carried 
out logistic regression analyses of the effect of CNV carrier status on both 
educational and occupational attainment, with and without Fluid Intelligence Test 
score included as a covariate (as it has the largest effect size) (Table S7). Prior to 
analysis, we dichotomized educational attainment, putting college/university degree 
into a single group and the remaining categories into a single group. For 
occupational attainment, we put managerial and professional occupations into a 
single group and the remaining occupational categories into a single group. This was 
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done in order to allow logistic regression analysis (although we are aware that this 
causes some loss of power, reflected in the more modest p-values, compared to the 
results from ordinal regression presented in the main text). In the case of educational 
attainment, approximately a half to two thirds of the adverse effect of CNV status 
was explained by the effect of the Fluid Intelligence Test score. In the case of 
occupational attainment, the results differed a bit between the carriers of 
schizophrenia CNVs (about two thirds explained) and the “other CNVs (about one 
third explained), perhaps due to the smaller sample size. In any case, these results 
indicate that other phenotypic consequences of having a pathogenic CNV (e.g. 
medical problems (or cognitive consequences not captured by the Fluid Intelligence 
Test) also affect educational and occupational attainment.  
 
Table S7. Regression results for the effect of carrying a CNV on educational and 
occupational attainment with and without Fluid Intelligence Test (FIT) score used as 
a covariate.  
 Without FIT Score 
Covariate 
With FIT Score 
Covariate 
B SE p B SE p 
Educational attainment 
Schizophrenia CNVs 
 
0.48 0.07 1.59x10-12 0.19 0.13 0.15 
Occupational attainment 
Schizophrenia CNVs 
 
0.39 0.09 6.0x10-6 0.11 0.14 0.42 
Educational attainment 
Other Neurodevelopmental CNVs 
 
0.62 0.10 1.74x10-9 0.18 0.19 0.35 
Occupational attainment 
Other Neurodevelopmental CNVs 
 
0.55 0.14 6.2x10-5 0.40 0.23 0.08 
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Analysis of Phenotypes of Carriers of Deletions and Duplications at 
16p11.2 and 17p12 
 
Table S8. BMI, height and weight in 16p11.2 CNV carriers. The results are 
expressed as differences in weight and height (kg and cm), after linear regression 
analyses controlled for age and sex. Deletion carriers have increased BMI, while 
duplication carriers have reduced BMI.  
 16p11.2 deletions (n = 44) 16p11.2 duplications (n = 42) 
 
 B 95% CI p B 95% CI p 
BMI 7.25 
 
5.82 to 8.68 2.8x10-23 -1.81 -3.27 to -0.35 0.015 
Height (cm) -7.29 -9.19 to -5.39 
 
6.2x10-14 3.0 1.05 to 4.95 0.003 
Weight (kg) 12.36 8.10 to 16.61 
 
1.3x10-8 -2.51 -6.87 to 1.85 0.26 
 
 
Table S9. Linear regression analyses for cognitive test results and 16p11.2 CNV 
carrier status. 
Cognitive Test 16p11.2 del 16p11.2 dup 
n B (SE) P n B (SE) P 
Pairs Matching Test  34 0.325 
(0.169) 
0.055 42 
 
-0.028 
(0.152) 
0.854 
Reaction Time Test 37 0.636 
(0.155) 
4.2×10-5 42 0.684 
(0.146) 
3.0×10-6 
Fluid Intelligence Test 10 -0.635 
(0.315) 
0.044 12 -1.028 
(0.288) 
3.51×10-4 
Digit Span 4 -0.823 
(0.496) 
0.097 3 -1.165 
(0.572) 
0.042 
Symbol Digit Substitution 1 -1.096 
(0.900) 
n.a. 8 -0.477 
(0.318) 
0.134 
TMTA 1 1.057 
(0.949) 
n.a. 7 1.217 
(0.359) 
0.001 
TMTB 1 0.863 
(0.923) 
n.a. 7 1.309 
(0.349) 
1.77×10-4 
 
n – number of CNV carriers, B – unstandardized coefficient (z score difference), SE – 
standard error, P-value. Significant results are in bold. No p-values are shown where only 
one person completed the test.  
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Table S10. Rates of 17p12 deletions and duplications and the frequency of 
peripheral neuropathy among the genotyped UK Biobank participants. The rate of 
self-reported peripheral neuropathy in deletion carriers is 32 times higher than in the 
rest of the population, and it is 133 times higher among duplication carriers. 
 17p12 del (HNPP) 17p12 dup (CMT1A) 
 N N Peripheral 
Neuropathy 
(%) 
Fisher’s 
Exact P 
N N Peripheral 
Neuropathy 
(%) 
Fisher’s 
Exact P 
Carriers 84 4         
(4.8%) 
1.0x10-6 45 9         
(20%) 
3x10-17 
Non-carriers 151,575 226             
(0.15%) 
151,614 221  
(0.15%) 
 
 
Table S11. Linear regression analyses for cognitive test results in 17p12 CNV 
carriers. Neither deletion nor duplication carriers show cognitive deficits and a higher 
proportion of them completed the tests, compared to 16p11.2 carriers. 
Cognitive Test 17p12 del (HNPP) 17p12 dup (CMT1A) 
n B (SE) P n B (SE) P 
Pairs Matching Test (Z) 77 0.001 
(0.002) 
0.62 37 4.37x10-5 
(0.002) 
0.98 
Reaction Time Test (Z) 76 -0.001 
(0.001) 
0.31 39 0.002 
(0.002) 
0.38 
Fluid Intelligence Test (Z) 23 -0.004 
(0.003) 
0.15 14 -0.002 
(0.004) 
0.55 
Digit Span (Z) 7 0.001 
(0.005) 
0.79 5 0.009 
(0.006) 
0.12 
Symbol Digit Substitution (Z) 18 -0.001 
(0.003) 
0.80 13 -0.005 
(0.003) 
0.14 
TMTA (Z) 17 0.005 
(0.003) 
0.083 11 0.005 
(0.004) 
0.22 
TMTB (Z) 17 0.005 
(0.003) 
0.085 11 0.002 
(0.004) 
0.61 
n = number of CNV carriers who have completed the test, B – unstandardized coefficient (z 
scores), SE – standard error, P-value. 
 
 
 
 
 
Table S12. Numbers of CNVs found in each batch. Batches -1 to -11 are the BiLEVE 
arrays. Results are shown for all 93 targeted loci but if no CNVs were found at a 
locus, this locus is not shown. No filtering for ethnicity has been applied here. 
 
See Supplement 2 (Excel file) for Table S12. 
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